A review on the role of tau and stathmin in gastric cancer metastasis

Gastric cancer is resistant to chemotherapy, especially in the later stages. The prevalence of gastric cancer increases after the age of 40, and its peak is in the 7th decade of life. The proteins tau (tubulin associated unit) and stathmin are overexpressed in gastric cancer and contribute to the progression of the disease by increasing cancer cell proliferation, invasion, and inducing drug resistance. This review summarizes the current knowledge on the expression of tau protein and stathmin in gastric cancer and their roles in drug resistance. Medline and PubMed databases were searched from 1990 till February 2021 for the terms tau protein, stathmin, and gastric cancer. Two reviewers screened all articles and assessed prognostic studies on the role of tau and stathmin proteins in gastric cancer progression. Collectively, studies reported that both proteins are expressed at different concentrations in gastric cancer and could be significant molecular biomarkers for prognosis. Both proteins could be good candidates for targeted therapy of gastric cancer and are associated with resistance to taxanes.

Automated summary

Gastric cancer shows resistance to chemotherapy, with tau protein and stathmin being overexpressed in the cancer cells, contributing to disease progression. They could serve as significant molecular biomarkers for prognosis in gastric cancer, and potential candidates for targeted therapy, particularly in cases resistant to taxanes.